$2.46
-0.09 (-3.35%)
Open$2.64
Previous Close$2.54
Day High$2.66
Day Low$2.39
52W High$7.65
52W Low$3.91
Volume—
Avg Volume872.7K
Market Cap241.60M
P/E Ratio—
EPS$-1.12
SectorBiotechnology
Analyst Ratings
Strong Buy
12 analysts
Price Target
+473.9% upside
Current
$2.46
$2.46
Target
$14.09
$14.09
$7.81
$14.09 avg
$15.42
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 4.89M | 3.05M | 39.71M |
| Net Income | 59.78M | 33.54M | -4,431,314 |
| Profit Margin | 1,223.1% | 1,161.9% | -11.2% |
| EBITDA | 54.98M | 32.56M | -4,969,444 |
| Free Cash Flow | — | — | -4,447,710 |
| Rev Growth | +60.4% | +60.4% | +12.5% |
| Debt/Equity | 0.13 | 0.13 | 0.22 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $294.45 | -0.18% | 49.3 | 509.50B |
| AMGN | Amgen Inc | $467.06 | -0.22% | 26.5 | 248.84B |
| GILD | Gilead Sciences Inc | $167.95 | -1.05% | — | 208.28B |
| VRTX | Vertex Pharmaceuticals Inc | $542.62 | -0.81% | 34.5 | 137.12B |
| REGN | Regeneron Pharmaceuticals | $951.19 | -0.86% | 19.4 | 93.39B |
| ALNY | Alnylam Pharmaceuticals Inc | $156.65 | -2.00% | 7.7 | 20.98B |